These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 23314743)

  • 21. Normokalemic hyperaldosteronism in patients with resistant hypertension.
    Benchetrit S; Bernheim J; Podjarny E
    Isr Med Assoc J; 2002 Jan; 4(1):17-20. PubMed ID: 11802302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary aldosteronism in diabetic subjects with resistant hypertension.
    Umpierrez GE; Cantey P; Smiley D; Palacio A; Temponi D; Luster K; Chapman A
    Diabetes Care; 2007 Jul; 30(7):1699-703. PubMed ID: 17429062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The diagnosis of primary aldosteronism and separation of two major subtypes.
    Weinberger MH; Fineberg NS
    Arch Intern Med; 1993 Sep; 153(18):2125-9. PubMed ID: 8379804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Aldosterone/plasma renin activity ratio is a sensitive parameter for screening patients with primary aldosteronism].
    Zhang HL; Liu ZJ; Shao JM; Yan JT; Wang DW
    Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Oct; 34(10):873-6. PubMed ID: 17217709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aldosterone/renin ratio determines peripheral and central blood pressure values over a broad range.
    Tomaschitz A; Maerz W; Pilz S; Ritz E; Scharnagl H; Renner W; Boehm BO; Fahrleitner-Pammer A; Weihrauch G; Dobnig H
    J Am Coll Cardiol; 2010 May; 55(19):2171-80. PubMed ID: 20447545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary aldosteronism: A common and curable form of hypertension.
    Young WF
    Cardiol Rev; 1999; 7(4):207-14. PubMed ID: 10423672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mild hyperparathyroidism: a novel surgically correctable feature of primary aldosteronism.
    Maniero C; Fassina A; Seccia TM; Toniato A; Iacobone M; Plebani M; De Caro R; Calò LA; Pessina AC; Rossi GP
    J Hypertens; 2012 Feb; 30(2):390-5. PubMed ID: 22179087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacodynamic and pharmacokinetic characterization of the aldosterone synthase inhibitor FAD286 in two rodent models of hyperaldosteronism: comparison with the 11beta-hydroxylase inhibitor metyrapone.
    Rigel DF; Fu F; Beil M; Hu CW; Liang G; Jeng AY
    J Pharmacol Exp Ther; 2010 Jul; 334(1):232-43. PubMed ID: 20354176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Primary hyperaldosteronism--12 clinical cases].
    Telles EC; Machado FS; da Silva EP; Lutucuta S; Almeida G; Coucelo J; Vagueiro C
    Rev Port Cardiol; 1999 Sep; 18(9):801-12. PubMed ID: 10536470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostics of primary aldosteronism: is obligatory use of confirmatory tests justified?
    Myśliwiec J; Zukowski Ł; Grodzka A; Piłaszewicz A; Dragowski S; Górska M
    J Renin Angiotensin Aldosterone Syst; 2012 Sep; 13(3):367-71. PubMed ID: 22406967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can the dextroenantiomer of the aromatase inhibitor fadrozole be useful for clinical investigation of aldosterone-synthase inhibition?
    Ménard J; Pascoe L
    J Hypertens; 2006 Jun; 24(6):993-7. PubMed ID: 16685193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy.
    Schumacher CD; Steele RE; Brunner HR
    J Hypertens; 2013 Oct; 31(10):2085-93. PubMed ID: 24107737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Eplerenone on Resistance to Antihypertensive Medication in Patients with Primary or Secondary Hyperaldosteronism.
    Spence JD; Bogiatzi C; Kuk M; Dresser GK; Hackam DG
    J Transl Int Med; 2017 Jun; 5(2):93-99. PubMed ID: 28721341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selectivity of BI 689648, a Novel, Highly Selective Aldosterone Synthase Inhibitor: Comparison with FAD286 and LCI699 in Nonhuman Primates.
    Weldon SM; Cerny MA; Gueneva-Boucheva K; Cogan D; Guo X; Moss N; Parmentier JH; Richman JR; Reinhart GA; Brown NF
    J Pharmacol Exp Ther; 2016 Oct; 359(1):142-50. PubMed ID: 27481775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mineralocorticoids and blood pressure.
    Weinberger MH
    Curr Opin Nephrol Hypertens; 1994 Sep; 3(5):550-3. PubMed ID: 7804754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spironolactone is more effective than eplerenone at lowering blood pressure in patients with primary aldosteronism.
    Bloch MJ; Basile JN
    J Clin Hypertens (Greenwich); 2011 Aug; 13(8):629-31. PubMed ID: 21806775
    [No Abstract]   [Full Text] [Related]  

  • 37. Primary Aldosteronism and Effects of Two Mineralocorticoid Inhibitors.
    Abbott EC
    Can Med Assoc J; 1964 Jun; 90(25):1425. PubMed ID: 20327880
    [No Abstract]   [Full Text] [Related]  

  • 38. Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension.
    Karns AD; Bral JM; Hartman D; Peppard T; Schumacher C
    J Clin Hypertens (Greenwich); 2013 Mar; 15(3):186-92. PubMed ID: 23458591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study).
    Ito S; Itoh H; Rakugi H; Okuda Y; Yoshimura M; Yamakawa S
    Hypertension; 2020 Jan; 75(1):51-58. PubMed ID: 31786983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eplerenone improves carotid intima-media thickness (IMT) in patients with primary aldosteronism.
    Matsuda Y; Kawate H; Matsuzaki C; Sakamoto R; Shibue K; Ohnaka K; Anzai K; Nomura M; Takayanagi R
    Endocr J; 2016; 63(3):249-55. PubMed ID: 26727302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.